CardioDx, a US-based provider of healthcare diagnostics backed by General Electric (GE) and Intel Capital, has closed its series E round at $60m.
In March, the company had made a preliminary close at $57.5m.
Venture capital (VC) firms Longitude Capital, Acadia Woods Partners, Artiman Ventures, investment bank JP Morgan, and Bright Capital, the corporate venturing unit of Russia-based industrial conglomerate Ru-Com Group, participated in the round as new investors.
The rest of the E round consortium came from previous investors: VC firms Kleiner Perkins Caufield & Byers, Mohr Davidow Ventures, TPG Biotech, Pappas Ventures, DAG Ventures, Asset Management Group, as well as Intel Capital and GE Capital.
In May last year, US-based conglomerate General Electric made its first investment out of its GE Healthymagination corporate venturing fund with the $5m backing of California-based CardioDx.
The GE Healthymagination fund was launched in October 2009 to identify and partner with healthcare technology companies as part of a $6bn program by GE to boost healthy living.
GE Healthcare has made between 25 and 30 minority stake investments in the past 12 years and was introduced to CardioDx by the company’s original backers, US venture capital firm Kleiner Perkins Caufield & Byers, five years ago.
However, GE Healthcare has also worked closely with another of CardioDx’s backers, TPG Biotech, a life sciences investment arm of private equity firm TPG Capital where CardioDx’s founder, David Levison, used to work as a venture partner.
Semiconductor company Intel’s corporate venturing unit had previously led CardioDx’s series C round of $20m in 2009 while Mohr Davidow Ventures invested $9m as part of a $19m Series B in 2006, according to news provider VentureWire.